In 2020, pyrotinib combined with capetabine was recommended as a second-line treatment (category 1A) by the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guideline for HER2-positive metastatic breast cancer. Here, ERBB2 is linked to breast carcinoma.